

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/650,595 08/27/2003		Peilin Chen	02558B-069000US	7928	
20350	7590 10/19/2004	EXAMINER			
	AND TOWNSEND A	CHEN, STAC	CHEN, STACY BROWN		
TWO EMBAR EIGHTH FLO	CADERO CENTER OR		ART UNIT	PAPER NUMBER	
SAN FRANCI	SCO, CA 94111-3834		1648		

DATE MAILED: 10/19/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary		Application	on No.	Applicant(s)			
		10/650,59	95	CHEN ET AL.			
		Examiner		Art Unit			
		Stacy B C		1648			
Period fo	The MAILING DATE of this communication or Reply	appears on the	cover sheet with the	correspondence ad	ldress		
THE - Exte after - If the - If NO - Failu Any	ORTENED STATUTORY PERIOD FOR RE MAILING DATE OF THIS COMMUNICATIOnsions of time may be available under the provisions of 37 CFR SIX (6) MONTHS from the mailing date of this communication, e period for reply specified above is less than thirty (30) days, at period for reply is specified above, the maximum statutory per to reply within the set or extended period for reply will, by streply received by the Office later than three months after the med patent term adjustment. See 37 CFR 1.704(b).	DN. R 1.136(a). In no eve a reply within the statu riod will apply and wi atute, cause the app	ent, however, may a reply be t utory minimum of thirty (30) da Il expire SIX (6) MONTHS frool lication to become ABANDON	timely filed ays will be considered timel m the mailing date of this co IED (35 U.S.C. § 133).	ly. ommunication.		
Status							
1)	Responsive to communication(s) filed on 2	7 August 2003					
2a) <u>□</u>	This action is FINAL . 2b) This action is non-final.						
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposit	ion of Claims						
5) □ 6) □ 7) □ 8) ⊠ Applicat 9) □ 10) □	Claim(s) 1-25 is/are pending in the applicate 4a) Of the above claim(s) is/are withe Claim(s) is/are allowed. Claim(s) is/are rejected. Claim(s) is/are objected to. Claim(s) 1-25 are subject to restriction and sion Papers The specification is objected to by the Exam The drawing(s) filed on is/are: a) a Applicant may not request that any objection to Replacement drawing sheet(s) including the cor The oath or declaration is objected to by the	drawn from con for election required niner. accepted or b) the drawing(s) b prection is require	uirement. ☐ objected to by the e held in abeyance. So ed if the drawing(s) is o	ee 37 CFR 1.85(a). bjected to. See 37 CF			
,—		s Examiner. No	te the attached one	C Addon of formal	0 102.		
Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.							
2) Notice 3) Infor	et(s) te of References Cited (PTO-892) te of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449 or PTO/SB r No(s)/Mail Date		4) Interview Summar Paper No(s)/Mail [5) Notice of Informal 6) Other:	Date	O-152)		

Application/Control Number: 10/650,595

Art Unit: 1648

DETAILED ACTION

Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-12, drawn to a composition comprising serum in which is dissolved a plurality of heterologous antibodies directed to different antigens, classified in class 424, subclass 130.1.
 - II. Claims 13-25, drawn to a method of detecting antigens using a composition of serum in which is dissolved a plurality of heterologous antibodies directed to different antigens, classified in class 435, subclass 5.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the composition of serum containing a plurality of heterologous antibodies is useable in a method of inducing an immune response.

A search for the composition and the method of using the composition would be a serious search burden. Searching the literature for a composition will not necessarily reveal the composition's methods of use, such as the method of Group II. Because these inventions are distinct for the reasons given above and the literature search required for Group I is not coextensive for Group II, restriction for examination purposes as indicated is proper.

Application/Control Number: 10/650,595

Art Unit: 1648

2. The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier.

Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai, In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Application/Control Number: 10/650,595

Art Unit: 1648

3. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143). Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Conclusion

4. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Stacy B. Chen whose telephone number is 571-272-0896. The examiner can normally be reached on M-F (7:00-4:30). If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James C. Housel can be reached on 571-272-0902. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Stacy B. Chen

October 15, 2004